Overview

Temozolomide in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer

Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who have stage IIIB, stage IV, or recurrent non-small cell lung cancer.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Fox Chase Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Dacarbazine
Temozolomide
Criteria
DISEASE CHARACTERISTICS: Stage IIIB, IV, or recurrent non-small cell lung cancer for which
no curative therapy with surgery, radiation, or combination chemoradiotherapy exists
Chemotherapy-naive patients: No prior chemotherapy OR At least 6 months since prior
adjuvant, induction, or radiosensitizing chemotherapy OR Previously treated patients
(closed to accrual 8/01): No more than one prior chemotherapy regimen for relapsed or
metastatic disease AND/OR No more than one prior adjuvant, induction, or radiosensitizing
chemotherapy within the past 6 months Measurable or evaluable disease CNS metastases
allowed (previously treated metastases cannot be only site of measurable disease) No brain
metastases with prior whole body irradiation

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: Not
specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count at
least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL Renal: Creatinine no greater
than 2.0 mg/dL Other: Not pregnant or nursing Negative pregnancy test Fertile patients must
use effective contraception during and for 3 months after study No other active invasive
malignancies

PRIOR CONCURRENT THERAPY: Biologic therapy: Prior biologic therapy allowed Chemotherapy:
See Disease Characteristics At least 4 weeks since prior chemotherapy Endocrine therapy:
Not specified Radiotherapy: See Disease Characteristics Recovered from prior radiotherapy
Surgery: See Disease Characteristics